We thank Daungsupawong and Wiwanitkit for their interest in our manuscript. Our primary aim in this piece of work was to assess the acceptability of facemask sampling (FMS) within clinical settings.1 Questions raised by Daungsupawong and Wiwanitkit relating to sensitivity and specificity, as well as differences in viral load detected in FMS and upper respiratory tract sampling (URTS), were not the focus of this work. We note some relevant points from our other publications2, 3, 4 below:
-
•
Viral load kinetics of FMS and URTS are different during infection.
-
•
URTS is positive for longer periods of time following infection compared to FMS (ie URTS appears to be more sensitive than FMS for diagnosis of SARS-COV-2).
-
•
FMS associates with household transmission of SARS-COV-2 better than URTS following natural infection (ie FMS appears to be better than URTS at detecting those who are infectious with SARS-CoV-2).
Therefore, the desire of most study participants for confirmatory testing using URTS of a positive FMS result in this manuscript should not affect the use of FMS, since we foresee the two sampling modalities to have different clinical applications. A positive URTS confirms the diagnosis of SARS-CoV-2, while FMS would assess how infectious the same individual is to others. A non-infectious individual who has recovered from acute infection (ie URTS positive, but no longer FMS positive for instance) could then return to work sooner than requiring a negative URTS result. Furthermore, if FMS replaced standard facemasks in hospitals for healthcare workers, they may be able to detect those who test positive for SARS-CoV-2 prior to symptom onset, and possibly even before a positive URTS sample. An isolation policy developed based on timely FMS results could have significant impact on nosocomial transmission of respiratory viruses.
In summary, the biological questions raised by Daungsupawong and Wiwanitkit were not the focus of our paper and are discussed elsewhere. The current paper presents findings relating to acceptability of FMS for detecting infectious individuals within nosocomial settings, which, in combination with other work, will be crucial for designing better, more precise interventions that can reduce respiratory virus transmission within hospitals.
Funding
DP is supported by an NIHR Doctoral Research Fellowship (NIHR302338). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
CRediT authorship contribution statement
Daniel Pan: Conceptualization, Writing – original draft, Writing – review & editing. Manish Pareek: Supervision, Writing – review & editing. Michael R. Barer: Supervision, Writing – review & editing.
Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Footnotes
This article reflects the opinions of the author(s) and should not be taken to represent the policy of the Royal College of Physicians unless specifically stated.
References
- 1.Pan D, Williams C, Decker J, et al. Implementation of facemask sampling for the detection of infectious individuals with SARS-CoV-2 in high stakes clinical examinations – a feasibility study. Future Healthc J. 2024;11(4) doi: 10.1016/j.fhj.2024.100175. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Pan D, Williams CM, Decker J, et al. Exhaled SARS-CoV-2 RNA viral load kinetics measured by facemask sampling associates with household transmission. Clin Microbiol Infect. 2023;29(2):254.e1–254.e6. doi: 10.1016/j.cmi.2022.07.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Williams CM, Pan D, Decker J, et al. Exhaled SARS-CoV-2 quantified by face-mask sampling in hospitalised patients with COVID-19. J Infect. 2021;82(6):253–259. doi: 10.1016/j.jinf.2021.03.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Zhou J, Singanayagam A, Goonawardane N, et al. Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study. Lancet Microbe. 2023;4(8):e579–ee90. doi: 10.1016/S2666-5247(23)00101-5. [DOI] [PMC free article] [PubMed] [Google Scholar]